The synthroid legacy
America’s #1 Prescribed
Oral Branded Medication1*
with 65 years of experience2

Synthroid has been committed to treating hypothyroidism for 65 years.2

  • Millions of patients manage their hypothyroidism with Synthroid3†
  • 37% of patients who think they are on Synthroid are actually not4‡

*2015-2018.

†Based on a 2015 survey.

‡Mistaken generic users defined as those who reported taking Synthroid but were not taking a pill with the word “Synthroid” embossed on it.

From a 2017 online survey of 501 adults diagnosed with hypothyroidism and currently taking LT4 products.4

If you prefer Synthroid, it is accessible to your patients. When you choose to prescribe it, voice your preference to your patients and protect the prescription consistently.

Prescribing Synthroid

12 Precise Dosing Options

Synthroid offers 12 dosing options so you can dial in a precise and individualized dose.5

25 mcg
orange

50 mcg
white

75 mcg
violet

88 mcg
olive

100 mcg
yellow

112 mcg
rose

125 mcg
brown

137 mcg
turquoise

150 mcg
blue

175 mcg
lilac

200 mcg
pink

300 mcg
green

Tablets shown not actual size and may not represent actual color.

For additional dosing information, click here.

Protecting your script can ensure your patients receive Synthroid every time they refill their prescription.

Hypothyroid medications require precise dosing and careful monitoring

Thyroid disease spectrum

Abbreviations: AACE, American Association of Clinical Endocrinologists; NACB, National Academy of Clinical Biochemistry; TSH, thyroid-stimulating hormone.

TSH levels alone may not be diagnostic of a thyroid disorder. Additional laboratory testing and clinical findings may be necessary.

The goal is to achieve steady TSH levels within the appropriate therapeutic range.

Access and Savings

Eligible patients can save with our copay card

At least 90% of eligible, commercially insured patients who used the Synthroid copay card paid no more than $25 for a 30-day prescription§

See Terms and Conditions.

Synthroid Copay Card Registration
a direct-to-patient pharmacy program that offers patients a cash-pay option to receive SYNTHROID consistently and conveniently

Learn how
your
Synthroid
patients
can
pay as little as

$25

Per monthwith a
90-day
prescription*

Find Out How

*Other pricing available for 30 and 60 days.

Tablet shown not actual size and may not represent actual color.

Additional Synthroid Information
Dosing
Cost & Coverage
Patient Resources
Clinical Scenarios

References: 1. Data on file. IQVIA Top Branded Oral Rx Medication. AbbVie Inc. January 2019. 2. Lomenick JP, Wang L, Ampah SB, et al. Generic levothyroxine compared with Synthroid in young children with congenital hypothyroidism. J Clin Endocrinol Metab. 2013;98(2):653-658. 3. Data on file. Branded Drugs & Thyroid Market and Naturals. AbbVie Inc. 2015. 4. Data on file. Synthroid Consumer AAU report. AbbVie Inc. 2017. 5. SYNTHROID [package insert]. North Chicago, IL: AbbVie Inc. 6. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028. 7. Demers LM, Spencer CA, eds; National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: laboratory support for the diagnosis of thyroid disease. https://www.aacc.org/-/media/Files/Science-and-Practice/Practice-Guidelines/Thyroid-Disease/ThyroidArchived2010.pdf. Published 2002. Accessed January 27, 2021.

INDICATION5

Hypothyroidism
SYNTHROID® (levothyroxine sodium) tablets, for oral use is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression
SYNTHROID is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Limitation of Use5

SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and over-treatment with SYNTHROID may induce hyperthyroidism.

SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

IMPORTANT SAFETY INFORMATION5
WARNING:
Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • SYNTHROID is contraindicated in patients with uncorrected adrenal insufficiency.
  • In the elderly and in patients with cardiovascular disease, SYNTHROID should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease. If cardiac symptoms develop or worsen, the SYNTHROID dose should be reduced or withheld for one week and restarted at a lower dose.
  • Patients with coronary artery disease who are receiving SYNTHROID should be monitored closely during surgical procedures for cardiac arrhythmias. Monitor patients during concomitant administration of SYNTHROID and sympathomimetic agents for signs and symptoms of coronary insufficiency.
  • Use of oral thyroid hormone is not recommended in myxedema coma. Products formulated for IV administration should be used to treat myxedema coma.
  • Patients with adrenal insufficiency should be treated with replacement glucocorticoids prior to initiating treatment with SYNTHROID. Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated.
  • SYNTHROID has a narrow therapeutic index. Regardless of the indication for use, careful dosage titration is necessary to avoid the consequences of over- or under-treatment.
  • Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing SYNTHROID.
  • Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in postmenopausal women. To mitigate this risk, patients receiving SYNTHROID should be given the minimum dose necessary that achieves the desired response.
  • Adverse reactions associated with SYNTHROID therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some foods affect thyroid hormone pharmacokinetics and metabolism and may alter the therapeutic response to SYNTHROID. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. Prescribers should consult appropriate reference sources for additional information on drug or food interactions with SYNTHROID.
  • SYNTHROID should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated. TSH levels may increase during pregnancy, so TSH should be monitored and SYNTHROID dose adjusted as needed.
Please click here for Full Prescribing Information.
INDICATION5

Hypothyroidism
SYNTHROID® (levothyroxine sodium) tablets, for oral use is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression
SYNTHROID is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Limitation of Use5

SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and over-treatment with SYNTHROID may induce hyperthyroidism.

SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

IMPORTANT SAFETY INFORMATION5
WARNING:
Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • SYNTHROID is contraindicated in patients with uncorrected adrenal insufficiency.
  • In the elderly and in patients with cardiovascular disease, SYNTHROID should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease. If cardiac symptoms develop or worsen, the SYNTHROID dose should be reduced or withheld for one week and restarted at a lower dose.
  • Patients with coronary artery disease who are receiving SYNTHROID should be monitored closely during surgical procedures for cardiac arrhythmias. Monitor patients during concomitant administration of SYNTHROID and sympathomimetic agents for signs and symptoms of coronary insufficiency.
  • Use of oral thyroid hormone is not recommended in myxedema coma. Products formulated for IV administration should be used to treat myxedema coma.
  • Patients with adrenal insufficiency should be treated with replacement glucocorticoids prior to initiating treatment with SYNTHROID. Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated.
  • SYNTHROID has a narrow therapeutic index. Regardless of the indication for use, careful dosage titration is necessary to avoid the consequences of over- or under-treatment.
  • Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing SYNTHROID.
  • Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in postmenopausal women. To mitigate this risk, patients receiving SYNTHROID should be given the minimum dose necessary that achieves the desired response.
  • Adverse reactions associated with SYNTHROID therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some foods affect thyroid hormone pharmacokinetics and metabolism and may alter the therapeutic response to SYNTHROID. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. Prescribers should consult appropriate reference sources for additional information on drug or food interactions with SYNTHROID.
  • SYNTHROID should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated. TSH levels may increase during pregnancy, so TSH should be monitored and SYNTHROID dose adjusted as needed.
Please click here for Full Prescribing Information.